Nicole Gaudelli, Ph.D.

Nicole Gaudelli, Ph.D.

Nicole Gaudelli received her B.S. degree in biochemistry from Boston College in 2006 where she studied the structural and mechanistic underpinnings of neocarzinostatin biosynthesis and a non-heme iron oxygenase involved in vancomycin assembly. She earned her Ph.D. in chemistry from Johns Hopkins University where she studied monocyclic beta-lactam antibiotics and elucidated the mechanism through which they are biosynthesized. She completed her postdoctoral fellowship at Harvard University in the laboratory of Professor David R. Liu where she expanded the capabilities of base editing technology by creating the first adenine base editor (ABE) through 7 rounds of directed evolution and engineering. Both her doctoral and postdoctoral work culminated in prominent Nature publications in the fields of natural product chemistry and gene editing respectively.

Dr. Gaudelli is an inventor on numerous base editing patents and leads the gene editing technologies platform group at Beam Therapeutics where her team advances precision genetic medicines using base editors. Dr. Gaudelli is a recipient of the 2018 American Chemical Society’s “Talented 12” award, recognized as a 2018 STAT News Wunderkind, a 2018 TEDMED Hive honoree, Genetic Engineering and Biotechnology News “Top 10 Under 40 of 2019”, BioSpace’s 2019 “10 Life Science Innovators Under 40 to Watch”, and is MIT’s 2019 Technology Reviews’ 35 Innovators Under 35.